MedTrace Logo

A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis

NCT02193815 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2016-06-09

Study results available
· View outcomes & findings →

Summary

This is a vehicle and comparator controlled Proof of Mechanism (PoM) trial to evaluate the effect on psoriasis disease activity and safety of topically applied PF 06263276 in subjects with psoriasis vulgaris.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

PF06263276

4% PF 06263276 solution Daily dosage: approximately 8 mg PF 06263276 QD

OTHER

Vehicle

Active ingredient-free vehicle to 4% solution

DRUG

2%Tofacitinib Ointment

Daily Dosage: approximately 4 mg tofacitinib

OTHER

Vehicle

Active ingredient-free vehicle to 2% Ointment

DRUG

Daivonex

Daivonex solution (50 ug/ml Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg

DRUG

Daivonex Ointment

Daivonex ointment (50 ug/g Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02193815 on ClinicalTrials.gov